跳至主要内容
临床试验/JPRN-jRCT1030230268
JPRN-jRCT1030230268招募中Unknown

Influence of dosing interval on immune-related adverse events and infusion reaction of nivolumab and pembrolizumab

none none0 个研究点目标入组 400 人开始时间: 2023年7月29日最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Patients treated with nivolumab monotherapy or pembrolizumab monotherapy at Kitasato University Hospital from April 1, 2019, to March 31, 2023

排除标准

  • (i) Patients who switched from the old regimen to the new regimen
  • (ii) Patients who could not continue more than 2 courses of the old regimen when only the old regimen was administered
  • (iii) Patients with missing data in the survey items

研究者

发起方
none none

相似试验